Free Trial

Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of "Buy" by Brokerages

Phreesia logo with Medical background

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have earned a consensus recommendation of "Buy" from the eleven brokerages that are presently covering the company, MarketBeat.com reports. Eleven investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued a report on the stock in the last year is $31.64.

A number of equities analysts have commented on the company. Citigroup restated a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Truist Financial raised their price objective on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. DA Davidson lowered their price objective on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th.

View Our Latest Stock Analysis on PHR

Phreesia Stock Performance

Shares of NYSE PHR traded down $1.88 during trading hours on Thursday, reaching $26.80. 124,185 shares of the stock were exchanged, compared to its average volume of 455,840. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -36.18 and a beta of 0.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. Phreesia has a 52 week low of $17.07 and a 52 week high of $30.53. The stock's fifty day simple moving average is $26.32 and its 200 day simple moving average is $26.35.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%. The firm had revenue of $115.94 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the company earned ($0.05) EPS. The company's revenue was up 14.5% on a year-over-year basis. Sell-side analysts predict that Phreesia will post -1.1 EPS for the current year.

Insider Activity at Phreesia

In related news, Director Michael Weintraub sold 2,569 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $27.86, for a total transaction of $71,572.34. Following the sale, the director owned 143,039 shares of the company's stock, valued at $3,985,066.54. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP David Linetsky sold 23,729 shares of the firm's stock in a transaction on Friday, June 27th. The shares were sold at an average price of $28.50, for a total value of $676,276.50. Following the sale, the senior vice president directly owned 193,510 shares in the company, valued at approximately $5,515,035. This trade represents a 10.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,781 shares of company stock worth $1,504,911 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phreesia

Hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in Phreesia by 10.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock worth $12,415,000 after buying an additional 46,209 shares during the period. Deutsche Bank AG lifted its holdings in Phreesia by 95.9% during the 4th quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock worth $1,442,000 after buying an additional 28,047 shares during the period. Bessemer Group Inc. lifted its holdings in Phreesia by 23.2% during the 1st quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock worth $1,222,000 after buying an additional 8,978 shares during the period. SG Americas Securities LLC acquired a new position in Phreesia during the 1st quarter worth about $462,000. Finally, Raymond James Financial Inc. acquired a new position in Phreesia during the 4th quarter worth about $379,000. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Company Profile

(Get Free Report

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Featured Articles

Analyst Recommendations for Phreesia (NYSE:PHR)

Should You Invest $1,000 in Phreesia Right Now?

Before you consider Phreesia, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.

While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines